Crit Care:可乐定用于机械通气人群镇静的有效性和安全性评价

2017-04-26 李潇潇;贾朝娟 环球医学

2017年2月,发表在《Crit Care》的一项研究调查了可乐定作为需要有创性机械通气的危重患者镇静的有效性和安全性。研究结果显示,目前已有数据仍不足以支持可乐定作为机械通气人群镇静的常规使用。背景:这项系统评价和荟萃分析调查了可乐定作为需要有创性机械通气的危重患者镇静的有效性和安全性。方法:研究者对MEDLINE、EMBASE、CINAHL和Cochrane试验注册库开展了全面的检索。研究者识


2017年2月,发表在《Crit Care》的一项研究调查了可乐定作为需要有创性机械通气的危重患者镇静的有效性和安全性。研究结果显示,目前已有数据仍不足以支持可乐定作为机械通气人群镇静的常规使用。

背景:这项系统评价和荟萃分析调查了可乐定作为需要有创性机械通气的危重患者镇静的有效性和安全性。

方法:研究者对MEDLINE、EMBASE、CINAHL和Cochrane试验注册库开展了全面的检索。研究者识别出比较危重患者可乐定和任何非可乐定方案的RCTs,排除需要机械通气的新生儿。采用GRADE方法评估证据的确定性。

结果:研究者纳入8项RCTs(n=642名患者)。在7项试验中,可乐定用于辅助而不是单独镇静。可乐定的机械通气时间(平均差(MD)0.05日,95%置信区间(CI)=-0.65一对0.75,I2=86%,中等确定性)、ICU死亡率(相对风险(RR)0.98,95%CI=0.51~1.90,I2=0%,低等确定性)或ICU住院时长(MD 0.04日,95%CI=-0.46~0.53,I2=16%,中等确定性)没有差异。可乐定使用的麻醉剂总剂量显着减少(标准平均差(SMD)-0.26,95%CI=-0.50~-0.02,I2=0%,中等确定性)。可乐定与临床显着低血压发生率增加相关(RR 3.11,95%CI=1.64~5.87,I2=0%,中等确定性)。

结论:直到开展进一步RCTs,数据仍不足以支持可乐定作为机械通气人群镇静的常规使用。可乐定或可节约麻醉剂,但会增加临床显着低血压的风险。

原始出处:

Wang JG, Belley-Coté E, Burry L, et al. Clonidine for sedation in the critically ill: a systematic review and meta-analysis. Crit Care. 2017 Feb 25.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1683407, encodeId=3f81168340ec4, content=<a href='/topic/show?id=a27838412cd' target=_blank style='color:#2F92EE;'>#可乐定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38412, encryptionId=a27838412cd, topicName=可乐定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217127964539, createdName=vera_1212, createdTime=Fri Jan 19 18:09:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444208, encodeId=93e2144420850, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Apr 28 11:09:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569578, encodeId=70e915695e83e, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Fri Apr 28 11:09:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190972, encodeId=d9381909e2ab, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Thu Apr 27 06:58:39 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190962, encodeId=a81319096231, content=分析的透彻学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:25:25 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1683407, encodeId=3f81168340ec4, content=<a href='/topic/show?id=a27838412cd' target=_blank style='color:#2F92EE;'>#可乐定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38412, encryptionId=a27838412cd, topicName=可乐定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217127964539, createdName=vera_1212, createdTime=Fri Jan 19 18:09:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444208, encodeId=93e2144420850, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Apr 28 11:09:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569578, encodeId=70e915695e83e, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Fri Apr 28 11:09:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190972, encodeId=d9381909e2ab, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Thu Apr 27 06:58:39 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190962, encodeId=a81319096231, content=分析的透彻学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:25:25 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2017-04-28 huagfeg
  3. [GetPortalCommentsPageByObjectIdResponse(id=1683407, encodeId=3f81168340ec4, content=<a href='/topic/show?id=a27838412cd' target=_blank style='color:#2F92EE;'>#可乐定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38412, encryptionId=a27838412cd, topicName=可乐定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217127964539, createdName=vera_1212, createdTime=Fri Jan 19 18:09:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444208, encodeId=93e2144420850, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Apr 28 11:09:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569578, encodeId=70e915695e83e, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Fri Apr 28 11:09:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190972, encodeId=d9381909e2ab, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Thu Apr 27 06:58:39 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190962, encodeId=a81319096231, content=分析的透彻学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:25:25 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2017-04-28 by2014
  4. [GetPortalCommentsPageByObjectIdResponse(id=1683407, encodeId=3f81168340ec4, content=<a href='/topic/show?id=a27838412cd' target=_blank style='color:#2F92EE;'>#可乐定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38412, encryptionId=a27838412cd, topicName=可乐定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217127964539, createdName=vera_1212, createdTime=Fri Jan 19 18:09:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444208, encodeId=93e2144420850, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Apr 28 11:09:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569578, encodeId=70e915695e83e, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Fri Apr 28 11:09:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190972, encodeId=d9381909e2ab, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Thu Apr 27 06:58:39 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190962, encodeId=a81319096231, content=分析的透彻学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:25:25 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2017-04-27 lou.minghong

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1683407, encodeId=3f81168340ec4, content=<a href='/topic/show?id=a27838412cd' target=_blank style='color:#2F92EE;'>#可乐定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38412, encryptionId=a27838412cd, topicName=可乐定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217127964539, createdName=vera_1212, createdTime=Fri Jan 19 18:09:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444208, encodeId=93e2144420850, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Apr 28 11:09:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569578, encodeId=70e915695e83e, content=<a href='/topic/show?id=436d3841186' target=_blank style='color:#2F92EE;'>#可乐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38411, encryptionId=436d3841186, topicName=可乐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eede15532060, createdName=by2014, createdTime=Fri Apr 28 11:09:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190972, encodeId=d9381909e2ab, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Thu Apr 27 06:58:39 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190962, encodeId=a81319096231, content=分析的透彻学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 06:25:25 CST 2017, time=2017-04-27, status=1, ipAttribution=)]
    2017-04-27 大爰

    分析的透彻学习了!

    0

相关资讯

JCO:埃罗替尼、质子泵抑制剂同服,理想再来点可乐

 埃罗替尼是一种口服酪氨酸激酶抑制剂,对于治疗非小细胞肺癌有着很好的效果。埃罗替尼口服的优势导致了一个新的相关的问题。埃罗替尼的胃肠道吸收是一个复杂的多因素导致的过程。其中影响吸收的最重要的一个因素就是胃内的pH。当埃罗替尼和质子泵抑制剂同服时,胃内pH值出现上升,直接导致了埃罗替尼生物利用度的下降。研究人员假设这两种药物的相互作用可以通过服用酸性可乐饮料逆转。 在这项随机、交

不能多喝可乐----可乐进入人体后变化图谱

疾病预防控制中心(CDC)的相关数据显示,在任何一天都有大约一半的美国居民饮用含糖饮料,其中青少年和年轻人消费量是最高的。一罐可乐中大约添加了10茶匙的糖。但世界卫生组织(WHO)推荐民众每日糖的食用量不要超过6茶匙,这意味着,即便我们每天只喝一罐可乐,每日糖类摄入量也是超标的。因此,含糖饮料的消费量居高不下会引起机体产生一系列健康问题。根据哈佛大学公共卫生学院的研究,每日饮用含糖饮料1-2罐的民

一起可乐引发的“血案”!

导语:只喝饮料不喝水时,就容易发生这类“血案”!在春节过后,门诊诊室忽然来了位很特别的小患者:病例介绍:患者,男,12岁,因疲劳、四肢肌肉无力1个月由家人轮椅推入诊室,无头晕、头痛、腹泻等其他表现,既往体健。查体:身高152 cm,体重78 kg,血压100/70 mmHg,查体时发现四肢肌张力减低,肌力Ⅳ级。外院头颅CT及MRI检查提示未见明显异常;我院检验提示:血钾2.6 mmol/L,钠13